Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients.

ABSTRACT:

Background

This study aimed to evaluate the concordance of oncogenic driver mutations between tumor tissues and circulating tumor DNA (ctDNA) in patients with lung cancer. In addition, this study attempted to reveal the clinical utility of ctDNA in lung cancer treatment.

Methods

Recurrent or metastatic non-small cell lung cancer (NSCLC) patients were prospectively enrolled in this study. Tumor tissue and serial blood samples were obtained from newly diagnosed patients (Cohort A) or patients treated with targeted therapy (Cohort B) and targeted gene panel sequencing was conducted to identify tumor mutational profiles.

Results

At the time of diagnosis, patients in Cohort A with a high cell-free DNA (cfDNA) concentration had poorer overall survival than those with a low

SUBMITTER: Kim S 

PROVIDER: S-EPMC10326792 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature